echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Positive phase 3 clinical data of Sanofi / regenerant PD-1 inhibitor in the first-line treatment of lung cancer

    Positive phase 3 clinical data of Sanofi / regenerant PD-1 inhibitor in the first-line treatment of lung cancer

    • Last Update: 2019-11-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, regeneron announced that the mid-term data analysis showed that libtayo, a PD-1 inhibitor jointly developed with Sanofi, as a single drug therapy, showed significantly better efficacy than chemotherapy in the three-stage clinical trials of first-line treatment of advanced non-small cell lung cancer (NSCLC) At present, libtayo is being used as a single drug in two phase 3 clinical trials, or in combination with chemotherapy for patients with advanced NSCLC No matter in the world or in China, lung cancer is the leading cause of cancer death Every year, more than 780000 people in China are diagnosed with lung cancer, and more than 620000 people die as a result Lung cancer can be roughly divided into small cell lung cancer and NSCLC NSCLC is the most common type of lung cancer, accounting for 80% - 85% of the total number of lung cancer Among NSCLC patients, 25% - 30% of them are squamous NSCLC patients and 70% - 75% of them are non squamous NSCLC patients Most NSCLC patients are advanced at the time of diagnosis, and the five-year survival rate is only 10% Libtayo is a humanized anti-PD-1 monoclonal antibody jointly developed by Sanofi and Zaiyuan company It helps the immune system kill tumor cells by blocking the PD-1 signal pathway Previously, it has been approved in the United States, the European Union, Canada and Brazil for the treatment of metastatic skin squamous cell carcinoma (CSCC) or local advanced CSCC patients who cannot receive curative surgery or radiotherapy In addition, libtayo is also treating cervical cancer, head and neck squamous cell carcinoma, melanoma, colorectal cancer, prostate cancer, multiple myeloma, Hodgkin's lymphoma and non Hodgkin's lymphoma patients in clinical trials In the phase 3 clinical trial of libtayo as a single drug therapy for NSCLC patients with PD-L1 expression level ≥ 50%, the patients involved had stage IIIB, IIIc or stage IV squamous or non squamous NSCLC, which was not suitable for chemotherapy and radiotherapy, nor had they received systemic treatment for advanced diseases The mid-term analysis of the trial showed that 42% of the patients receiving libtayo had orr compared with those receiving chemotherapy alone, which was very similar to that of keytruda (39%) who was becoming the standard nursing therapy for some lung cancer patients in the previous three trials, compared with 22% in the chemotherapy group We hope that this PD-1 inhibitor can bring us more good news and provide more treatment options for lung cancer patients! reference material: [1] Regeneron Provides Updates on Phase 3 Libtayo® (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer, Retrieved November 6, 2019, from https://www.prnewswire.com/news-releases/regeneron-provides-updates-on-phase-3-libtayo-cemiplimab-development-program-in-advanced-non-small-cell-lung-cancer-300951372.html [2] Regeneron’s Libtayo shows response rate in line with Keytruda’s in first-line NSCLC, Retrieved November 6, 2019, from https://www.biocentury.com/bc-extra/clinical-news/2019-11-05/regeneron’s-libtayo-shows-response-rate-line-keytruda’s-first- A kind of
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.